Oramed Pharmaceuticals Inc. (ORMP.TA)
ILA 879.9
(4.22%)
ILA 879.9
(4.22%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 36.9 Million USD | 0.31% |
| 2021 | 36.78 Million USD | -6.63% |
| 2020 | 39.39 Million USD | -26.93% |
| 2019 | 53.91 Million USD | -8.02% |
| 2018 | 58.61 Million USD | -16.08% |
| 2017 | 69.84 Million USD | 10.96% |
| 2016 | 62.94 Million USD | 948.47% |
| 2015 | 6 Million USD | 72.83% |
| 2014 | 3.47 Million USD | 92.64% |
| 2013 | 1.8 Million USD | -70.38% |
| 2012 | 6.08 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q3 | 315.82 Million USD | 1402.42% |
| 2023 Q2 | 21.02 Million USD | -39.46% |
| 2023 Q1 | 34.72 Million USD | -5.91% |
| 2022 Q2 | 32.35 Million USD | 1.14% |
| 2022 Q1 | 31.99 Million USD | -8.04% |
| 2022 Q3 | 40.23 Million USD | 24.34% |
| 2022 Q4 | 36.9 Million USD | -8.28% |
| 2022 FY | 36.9 Million USD | 0.31% |
| 2021 Q2 | 36.69 Million ILA | -9.31% |
| 2021 Q1 | 40.46 Million USD | -4.04% |
| 2021 FY | 36.78 Million USD | -6.63% |
| 2021 Q3 | 36.78 Million USD | 0.24% |
| 2021 Q4 | 34.78 Million USD | -5.43% |
| 2020 Q2 | 42.28 Million USD | -11.66% |
| 2020 FY | 39.39 Million USD | -26.93% |
| 2020 Q1 | 47.86 Million USD | -1.51% |
| 2020 Q3 | 39.42 Million USD | -6.77% |
| 2020 Q4 | 42.16 Million USD | 6.96% |
| 2019 Q4 | 48.6 Million USD | -9.95% |
| 2019 Q3 | 53.97 Million USD | -6.22% |
| 2019 FY | 53.91 Million USD | -8.02% |
| 2019 Q2 | 57.55 Million USD | 211.12% |
| 2019 Q1 | 18.49 Million USD | 19.49% |
| 2018 Q1 | 61.81 Million USD | 245.22% |
| 2018 Q2 | 20.09 Million USD | -67.49% |
| 2018 FY | 58.61 Million USD | -16.08% |
| 2018 Q4 | 15.48 Million USD | -73.63% |
| 2018 Q3 | 58.71 Million USD | 192.16% |
| 2017 Q3 | 18.51 Million USD | -73.83% |
| 2017 Q2 | 70.72 Million USD | 293.81% |
| 2017 Q1 | 17.95 Million USD | -0.97% |
| 2017 FY | 69.84 Million USD | 10.96% |
| 2017 Q4 | 17.9 Million USD | -3.27% |
| 2016 Q1 | 22.14 Million USD | 326.15% |
| 2016 FY | 62.94 Million USD | 948.47% |
| 2016 Q4 | 18.13 Million USD | -71.14% |
| 2016 Q3 | 62.84 Million USD | 206.38% |
| 2016 Q2 | 20.51 Million USD | -7.39% |
| 2015 FY | 6 Million USD | 72.83% |
| 2015 Q3 | 5.99 Million USD | 93.16% |
| 2015 Q1 | 2.55 Million USD | -20.77% |
| 2015 Q2 | 3.1 Million USD | 21.64% |
| 2015 Q4 | 5.19 Million USD | -13.38% |
| 2014 Q3 | 3.47 Million USD | 102.1% |
| 2014 Q4 | 3.22 Million USD | -7.23% |
| 2014 FY | 3.47 Million USD | 92.64% |
| 2014 Q2 | 1.71 Million USD | 28.96% |
| 2014 Q1 | 1.33 Million USD | -43.43% |
| 2013 Q4 | 2.35 Million USD | 30.64% |
| 2013 Q3 | 1.8 Million USD | -28.89% |
| 2013 Q1 | 2.63 Million USD | 106.42% |
| 2013 FY | 1.8 Million USD | -70.38% |
| 2013 Q2 | 2.53 Million USD | -3.68% |
| 2012 Q3 | 6.08 Million USD | 0.0% |
| 2012 FY | 6.08 Million USD | 0.0% |
| 2012 Q4 | 1.27 Million USD | -79.05% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|